Medway school of pharmacy

I obtained my BSc (Hons) in Microbiology and Genetics from University College London (UCL) in 1990 and my MSc (1992), PhD (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). Prior to my appointment as a Senior Lecturer in Biological Sciences at the Medway School of Pharmacy I was a Principal Investigator at the MRC/UCL Centre for Medical Molecular Virology, Windeyer Institute, University College London. This post was funded by the MRC and industry. My research is focused primarily on antibody responses to SARS coronavirus, pandemic/inter-pandemic influenza and other emerging viruses. I have developed an independent research portfolio (http://public.me.com/nigel.temperton) on the use of retroviral pseudotypes as surrogates for the serological study of emerging viruses and have been invited to give many lectures/seminars/workshops at conferences, to public health institutes (human and veterinary) and to biotech and pharmaceutical companies. In previous posts, I have undertaken research on the development of DNA vaccines for cytomegalovirus (Post-Doctoral research at the Royal Free Hospital), and the role of superoxide dismutase in the response of Trypanosoma cruzi to trypanocidal agents (PhD research at LSHTM). I am a Member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Biochemical Society and the Society for General Microbiology (SGM).

back to top

My research interests lie primarily in emerging and transboundary viruses and the methods for their control. I have established novel virus neutralization assays for high-containment viruses (Influenza H5N1/H7N1, SARS coronavirus and rabies) using retroviral and lentiviral vector technologies. As this research is highly translational these assays are currently used here at the Medway School of Pharmacy and with collaborating laboratories worldwide for the evaluation of vaccine immunogenicity, antiviral screening and resistance, receptor/tropism studies and sero-surveillance. I maintain many active and productive collaborations (in the UK and worldwide) with public health laboratories (Health Protection Agency/WHO/Veterinary Laboratories Agency/OIE), vaccine clinical trial centers (University of Siena and CEVAC, Ghent) and industry (vaccine and biotech companies). Current projects in the laboratory include:

• The development of surface-engineered retroviral vectors to study the antigenic evolution of influenza H5 and H7 viruses in birds and humans.
• The development of novel serologic and pharmacologic assays for influenza neuraminidase (NA). These can be used to study (a) the protective role of NA antibodies elicited by vaccination and during natural infection, (b) the antigenic drift of neuraminidase and (c) the mechanism of resistance to antiviral drugs that target NA.
• Comparative serology for influenza viruses in order to establish more accurate correlates of immunity.
• The pre-clinical evaluation of monoclonal antibodies as novel therapeutics for influenza.
• The serological response to LPAI and HPAI influenza viruses in birds.
• The development of multiplex neutralization assays for emerging viruses using luminescence and fluorescence platforms.
• The translation of “sequence-file serology” to public health and industrial laboratories worldwide.

back to top

• Temperton NJ (2010). The Use of Retroviral Pseudotypes for the Measurement of Antibody Responses to SARS Coronavirus. Chapter 17 in Lal,S.K. (ed.) Molecular Biology of the SARS-Coronavirus. Berlin: Springer-Verlag.
• Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B (2009). Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 Influenza viruses: Vaccine 27, 5998-6003.
• Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, Gellini M, Alberini I, Pittiglio E, Donatelli I, Temperton NJ, Cianfriglia M (2009). Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1: Antiviral Research 83, 238-244.
• Oh S, Selleck P, Temperton NJ, Chan PK, Manavis J, Higgins G, Burrell CJ, Kok T (2009). Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 Viruses: Journal of Virological Methods 157, 161-167.
• Temperton NJ, Wright E (2009) Retroviral Pseudotypes. In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0021549.
• Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin SC, Screaton GR, Hou JL, McMichael AJ, Xu XN (2008). T Cell Responses to Whole SARS Coronavirus in Humans: Journal of Immunology 181, 5490-5500.
• Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA (2008). Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison: Journal of General Virology 89, 2204-2213.
• Su CY, Wang SY, Shie JJ, Jeng KS, Temperton NJ, Fang JM, Wong CH, Cheng YS (2008). In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Research 79, 199-205.
• Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha DQ, de Jong MD, Zambon M, Takeuchi Y, Weiss RA (2007). A Sensitive Retroviral Pseudotype Assay for Influenza H5N1 neutralizing antibodies: Influenza and other respiratory viruses 1, 105-112.
• Dye C, Temperton N, Siddell SG (2007). Type 1 feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines: Journal of General Virology 88, 1753-1760.
• Moyes D, Martin A, Sawcer S, Temperton N, Worthington J, Griffiths DJ, Venables PJ (2005). The distribution of the endogenous retroviruses HERV-K113 and –K115 in health and disease: Genomics 86, 336-341.
• Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeushi Y, Weiss RA (2005). Longitudinally profiling neutralizing antibody response to SARS Coronavirus with pseudotypes: Emerging Infectious Diseases 11, 411-416.
• Temperton NJ, Lawson KM, Quenelle DC, Zuckerman JN, Kern E, Griffiths PD, Emery VC (2003). Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminium phosphate and CpG ODN: Journal of Medical Virology 70, 86-90.

back to top